Antigen-specific β-chemokine production and CD8+ T-cell noncytotoxic antiviral activity in HIV-2-infected individuals

Scandinavian Journal of Immunology

Volumn 61, Issue 1, 2005, Pages 63-71

  Ahmed, R K S ^a,f   Norrgren, H ^b   Da Silva, Z ^c   Blaxhult, A ^d   Fredriksson, E L ^e   Biberfeld, G ^a   Andersson, S ^a   Thorstensson, R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c National Public Health Laboratory   (Guinea-Bissau)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CD8 ANTIGEN;

ADULT; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; ASYMPTOMATIC INFECTION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; GUINEA-BISSAU; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; R5 VIRUS; SWEDEN; SYMPTOMATOLOGY; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; X4 VIRUS;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CC; FEMALE; GUINEA-BISSAU; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MIDDLE AGED; RANTES; SWEDEN; VIRUS REPLICATION;

EID: 13244271360     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2005.01530.x     Document Type: Article

References (47)

1. Kanki PJ, Travers KUM, Boup S et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343 (8903):943-6.
2. Poulsen A, Kvinesdal B, Aaby P et al. Lack of evidence of vertical transmission of human immunodeficiency virus type 2 in a sample of the general population in Bissau. J Acquir Immune Defic Syndr 1992;5 (1):25-30.
3. Andreasson PA, Dias F, Naucler A, Andersson S, Biberfeld G. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 1993;7 (7):989-93.
4. Barker E, Mackewicz CE, Reyes-Teran G et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 1998;92 (9):3105-14.
5. Marlink R, Kanki P, Thior I et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265 (5178):1587-90.
6. Whittle H, Morris J, Todd J et al. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 1994;8 (11):1617-20.
7. Mörner A, Bjorndal A, Albert J et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999;73 (3):2343-9.
8. Sol N, Ferchal F, Braun J et al. Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. J Virol 1997:71 (11):8237-44.
9. Bron R, Klasse PJ, Wilkinson D et al. Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J Virol 1997;71 (11):8405-15.
10. Guillon C, van der Ende ME, Boers PH et al. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J Virol 1998;72 (7):6260-3.
11. McKnight A, Dittmar MT, Moniz-Periera J et al. A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J Virol 1998;72 (5):4065-71.
12. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234 (4783):1563-6.
13. + T cells. Immunol Today 1996;17 (5):217-24.
14. Harrer T, Harrer E, Kalams SA et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996;156 (7):2616-23.
15. Rinaldo C, Huang XL, Fan ZF et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995;69 (9):5838-42.
16. Rowland-Jones S, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1 (1):59-64.
17. Scala E, D'Offizi G, Rosso R et al. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 1997;158 (9):4485-92.
18. Stranford SA, Skurnick J, Louria D et al. Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response. Proc Natl Acad Sci USA 1999;96 (3):1030-5.
19. Ahmed RK, Nilsson C, Wang Y, Lehner T, Biberfeld G, Thorstensson R. β-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge. J Gen Virol 1999;80:1569-74.
20. Ahmed RK, Makitalo B, Karlen K, Nilsson C, Biberfeld G, Thorstensson R. Spontaneous production of RANTES and antigen-specific IFN-γ production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge. Clin Exp Immunol 2002;129 (1):11-8.
21. + cell-produced anti-viral factors in protective immunity in HIV-2-exposed but seronegative macaques resistant to intrarectal SIVsm challenge. Scand J Immunol 2001;53 (3):245-53.
22. + T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000;97 (25):13812-7.
23. + cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from β-chemokines. Viral Immunol 2000;13 (4):481-95.
24. Schim van der Loeff MF, Aaby P. Towards a better understanding of the epidemiology of HIV-2. AIDS 1999;13 (Suppl. A):S69-84.
25. Tartaglia J, Perkus ME, Taylor J et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992;188 (1):217-32.
26. Larsson M, Jin X, Ramratnam B et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999;13 (7):767-77.
27. Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272 (5270):1955-8.
28. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997;388 (6639):296-300.
29. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381 (6584):667-73.
30. + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA 1995;92 (6):2308-12.
31. + cell-derived anti-human immunodeficiency virus inhibitory factor. J Infect Dis 1999;179:S485-8.
32. + T cells is not lentivirus specific. AIDS Res Hum Retroviruses 1995;11 (11):1321-6.
33. Zagury D, Lachgar A, Chams V et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998;95 (7):3857-61.
34. Ullum H, Cozzi Lepri A, Victor J et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1β are associated with a decreased risk of HIV disease progression. J Infect Dis 1998;177 (2):331-6.
35. Ferbas J, Giorgi JV, Amini S et al. Antigen-specific production of RANTES, macrophage inflammatory protein (MIP)-1α, and MIP-1β in vitro is a correlate of reduced human immunodeficiency virus burden in vivo. J Infect Dis 2000;182 (4):1247-50.
36. Garzino-Demo A, Moss RB, Margolick JB et al. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999;96 (21):11986-91.
37. + T cell nonlytic suppressive factors by CD28, CD38, and HLA-DR subpopulations. AIDS Res Hum Retroviruses 2003;19 (6):497-502.
38. Brichacek B, Bukrinsky M. Highly active antiretroviral therapy and beta-chemokines. Clin Exp Immunol 2002;130 (2):169-71.
39. + T lymphocyte-mediated nonlytic suppression of autologous and heterologous primary human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1997;13 (8):685-93.
40. + T cell phenotype correlates with anti-HIV activity and asymptomatic clinical state. Clin Immunol Immunpath 1993;69:106-16.
41. + cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991;87 (4):1462-6.
42. + T lymphocytes from HIV-exposed-uninfected individuals. AIDS 2002;16 (7):1003-8.
43. Kokkotou EG, Sankale JL, Mani I et al. In vitro correlates of HIV-2-mediated HIV-1 protection. Proc Natl Acad Sci USA 2000;97 (12):6797-802.
44. + patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 1998;161 (11):6433-8.
45. Oliva A, Kinter AL, Vaccarezza M et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998;102 (1): 223-31.
46. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185 (4):621-8.
47. + T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells. AIDS Res Hum Retroviruses 1997;13:79-85.